UK's Cambridge Nutritional Sciences yearly revenue as geopolitical turmoil delays overseas orders

Cambridge Nutritional Sciences

22/04/2026 07:10

Overview

UK medical diagnostics firm's yearly revenue fell due to reduced orders in Middle East and Asia

Adjusted EBITDA for the year showed a loss, compared to a profit in 2025

Company's gross margin rose to 67.8% from 65.3% on cost control and efficiencies

Outlook

Company says it remains mindful of ongoing global uncertainties impacting trading conditions

Company continues to invest in IVDR development programme for future product and cost advantages

Result Drivers

GEOPOLITICAL DISRUPTION - Co said reduced and delayed orders from Middle East and Asia were due to geopolitical instability and uncertainty

UK AND INDIA GROWTH - Underlying revenue growth was driven in particular by the UK and Indian markets, according to CEO James Cooper

EFFICIENCIES AND COST CONTROL - Co said continued focus on efficiencies and cost control resulted in higher gross margin

Company press release: ID:nRSV3731Ba

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Gross Margin
67.80%


Analyst Coverage

Wall Street's median 12-month price target for Cambridge Nutritional Sciences PLC is GBp6.00, about 207.7% above its April 21 closing price of GBp1.95

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)